Takeda forecasts 17% profit decline on Velcade US exclusivity loss
Updated : May 14, 2018 12:24 PM IST
The decline, which is likely to be partly offset by growing sales of drugs such as bowel disease treatment Entyvio and heartburn and ulcer drug Takecab, underscores Takeda's need to bolster its pipeline.
It also comes days after it agreed to a record-breaking $62 billion deal to acquire London-listed Shire.
Entyvio sales grew 41% to 201.4 billion yen, with Takecab sales up 62% to 55.1 billion yen.